OncoCyte Historical Income Statement

OCX Stock

USD 2.44 0.09 3.56%

Historical analysis of OncoCyte Corp income statement accounts such as Other Operating Expenses of 23.2 M can show how well OncoCyte Corp performed in making a profits. Evaluating OncoCyte Corp income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of OncoCyte Corp's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining OncoCyte Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether OncoCyte Corp is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OncoCyte Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.

About OncoCyte Income Statement Analysis

OncoCyte Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to OncoCyte Corp shareholders. The income statement also shows OncoCyte investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

OncoCyte Corp Income Statement Chart

At this time, OncoCyte Corp's Selling General Administrative is fairly stable compared to the past year. Gross Profit is likely to rise to about 433.6 K in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.4 M in 2024.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of OncoCyte Corp. It is also known as OncoCyte Corp overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from OncoCyte Corp's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into OncoCyte Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OncoCyte Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.At this time, OncoCyte Corp's Selling General Administrative is fairly stable compared to the past year. Gross Profit is likely to rise to about 433.6 K in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.4 M in 2024.

OncoCyte Corp income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Net Income	Gross Profit	Net Income From Continuing Ops	Cost Of Revenue	Total Other Income Expense Net	Income Tax Expense	Interest Income	Selling And Marketing Expenses	Net Interest Income	Reconciled Depreciation	Non Operating Income Net Other	Tax Provision	Discontinued Operations	Non Recurring
Depreciation And Amortization		0.15	0.79	0.73	-0.58	-0.6	0.61	-0.52	0.72	-0.62	-0.94	0.37	-0.61	0.63	0.18	0.65	-0.12	0.49	-0.17	0.96	0.38	-0.38	0.12	-0.1
Interest Expense	0.15		0.65	0.64	-0.67	-0.66	0.65	-0.68	0.66	-0.59	-0.42	-0.54	-0.64	0.41	-0.34	-0.12	0.47	0.59	-0.2	0.14	0.01	-0.31	-0.15	0.15
Selling General Administrative	0.79	0.65		0.95	-0.88	-0.87	0.88	-0.84	0.96	-0.82	-0.94	0.0	-0.83	0.69	-0.14	0.4	0.01	0.74	-0.18	0.82	0.12	-0.37	0.13	-0.14
Other Operating Expenses	0.73	0.64	0.95		-0.97	-0.97	0.97	-0.95	1.0	-0.95	-0.88	0.09	-0.95	0.86	0.02	0.15	0.0	0.9	-0.26	0.78	0.28	-0.56	0.2	-0.17
Operating Income	-0.58	-0.67	-0.88	-0.97		1.0	-0.98	0.99	-0.96	0.96	0.76	-0.1	0.96	-0.85	-0.11	0.04	-0.05	-0.93	0.18	-0.65	-0.27	0.56	-0.29	0.3
Ebit	-0.6	-0.66	-0.87	-0.97	1.0		-0.98	1.0	-0.96	0.98	0.77	-0.11	0.98	-0.89	-0.14	0.06	-0.04	-0.95	0.22	-0.66	-0.33	0.62	-0.25	0.25
Research Development	0.61	0.65	0.88	0.97	-0.98	-0.98		-0.97	0.97	-0.95	-0.78	0.06	-0.94	0.84	0.07	0.0	0.1	0.91	-0.26	0.68	0.26	-0.54	0.31	-0.25
Ebitda	-0.52	-0.68	-0.84	-0.95	0.99	1.0	-0.97		-0.94	0.97	0.71	-0.07	0.97	-0.87	-0.12	0.14	-0.05	-0.96	0.21	-0.59	-0.31	0.62	-0.25	0.25
Total Operating Expenses	0.72	0.66	0.96	1.0	-0.96	-0.96	0.97	-0.94		-0.92	-0.89	0.06	-0.93	0.81	-0.03	0.18	0.03	0.88	-0.24	0.78	0.21	-0.5	0.22	-0.18
Income Before Tax	-0.62	-0.59	-0.82	-0.95	0.96	0.98	-0.95	0.97	-0.92		0.75	-0.15	1.0	-0.96	-0.26	0.12	-0.01	-0.97	0.26	-0.65	-0.5	0.76	-0.16	0.16
Net Income	-0.94	-0.42	-0.94	-0.88	0.76	0.77	-0.78	0.71	-0.89	0.75		-0.19	0.75	-0.69	0.0	-0.57	0.05	-0.64	0.2	-0.94	-0.24	0.38	-0.12	0.13
Gross Profit	0.37	-0.54	0.0	0.09	-0.1	-0.11	0.06	-0.07	0.06	-0.15	-0.19		-0.09	0.24	0.68	0.12	-0.53	0.08	0.43	0.43	0.26	-0.08	0.62	-0.62
Net Income From Continuing Ops	-0.61	-0.64	-0.83	-0.95	0.96	0.98	-0.94	0.97	-0.93	1.0	0.75	-0.09		-0.95	-0.21	0.11	-0.03	-0.97	0.28	-0.64	-0.49	0.76	-0.1	0.11
Cost Of Revenue	0.63	0.41	0.69	0.86	-0.85	-0.89	0.84	-0.87	0.81	-0.96	-0.69	0.24	-0.95		0.37	-0.16	-0.08	0.94	-0.35	0.64	0.66	-0.88	0.05	-0.07
Total Other Income Expense Net	0.18	-0.34	-0.14	0.02	-0.11	-0.14	0.07	-0.12	-0.03	-0.26	0.0	0.68	-0.21	0.37		-0.31	-0.18	0.14	0.31	0.08	0.75	-0.47	0.3	-0.3
Income Tax Expense	0.65	-0.12	0.4	0.15	0.04	0.06	0.0	0.14	0.18	0.12	-0.57	0.12	0.11	-0.16	-0.31		-0.09	-0.23	0.04	0.61	-0.26	0.38	0.01	-0.02
Interest Income	-0.12	0.47	0.01	0.0	-0.05	-0.04	0.1	-0.05	0.03	-0.01	0.05	-0.53	-0.03	-0.08	-0.18	-0.09		-0.02	-0.48	-0.21	0.02	0.05	-0.13	0.13
Selling And Marketing Expenses	0.49	0.59	0.74	0.9	-0.93	-0.95	0.91	-0.96	0.88	-0.97	-0.64	0.08	-0.97	0.94	0.14	-0.23	-0.02		-0.37	0.56	0.42	-0.76	0.1	-0.13
Net Interest Income	-0.17	-0.2	-0.18	-0.26	0.18	0.22	-0.26	0.21	-0.24	0.26	0.2	0.43	0.28	-0.35	0.31	0.04	-0.48	-0.37		-0.17	-0.19	0.37	0.38	-0.38
Reconciled Depreciation	0.96	0.14	0.82	0.78	-0.65	-0.66	0.68	-0.59	0.78	-0.65	-0.94	0.43	-0.64	0.64	0.08	0.61	-0.21	0.56	-0.17		0.21	-0.3	0.28	-0.26
Non Operating Income Net Other	0.38	0.01	0.12	0.28	-0.27	-0.33	0.26	-0.31	0.21	-0.5	-0.24	0.26	-0.49	0.66	0.75	-0.26	0.02	0.42	-0.19	0.21		-0.86	-0.23	0.24
Tax Provision	-0.38	-0.31	-0.37	-0.56	0.56	0.62	-0.54	0.62	-0.5	0.76	0.38	-0.08	0.76	-0.88	-0.47	0.38	0.05	-0.76	0.37	-0.3	-0.86		0.29	-0.28
Discontinued Operations	0.12	-0.15	0.13	0.2	-0.29	-0.25	0.31	-0.25	0.22	-0.16	-0.12	0.62	-0.1	0.05	0.3	0.01	-0.13	0.1	0.38	0.28	-0.23	0.29		-0.8
Non Recurring	-0.1	0.15	-0.14	-0.17	0.3	0.25	-0.25	0.25	-0.18	0.16	0.13	-0.62	0.11	-0.07	-0.3	-0.02	0.13	-0.13	-0.38	-0.26	0.24	-0.28	-0.8

Click cells to compare fundamentals

OncoCyte Corp Account Relationship Matchups

OncoCyte Corp income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	344K	394K	4.2M	5.2M	1.7M	1.4M
Interest Expense	299K	252K	209K	77K	52K	49.4K
Selling General Administrative	13.3M	16.8M	22.3M	21.9M	10.7M	11.2M
Other Operating Expenses	22.2M	34.9M	54.7M	31.3M	26.6M	23.2M
Operating Income	(22.2M)	(29.7M)	(46.9M)	(18.0M)	(25.1M)	(26.4M)
Ebit	(22.0M)	(30.9M)	(52.7M)	(18.5M)	(24.8M)	(26.0M)
Research Development	6.8M	9.8M	13.6M	7.3M	9.3M	7.8M
Ebitda	(21.7M)	(30.5M)	(48.5M)	(13.3M)	(23.1M)	(24.3M)
Total Operating Expenses	22.2M	33.1M	47.1M	30.3M	25.6M	22.1M
Income Before Tax	(22.4M)	(31.2M)	(73.4M)	(18.6M)	(24.9M)	(26.1M)
Net Income	(22.3M)	(29.9M)	(64.1M)	(73.4M)	(27.8M)	(29.2M)
Total Revenue	16K	1.2M	7.7M	958K	1.5M	1.3M
Gross Profit	(344K)	(639K)	188K	(18K)	413K	433.7K
Net Income From Continuing Ops	(22.4M)	(29.9M)	(64.1M)	(18.6M)	(20.9M)	(21.9M)
Cost Of Revenue	344K	1.9M	7.5M	976K	1.1M	1.5M
Total Other Income Expense Net	(187K)	(1.5M)	854K	(615K)	281K	295.1K
Net Income Applicable To Common Shares	(22.4M)	(29.9M)	(64.1M)	(73.4M)	(66.1M)	(62.8M)
Income Tax Expense	(97K)	(1.3M)	(9.3M)	54.8M	2.9M	5.1M
Selling And Marketing Expenses	2.2M	6.5M	11.2M	1.1M	2.8M	3.6M
Net Interest Income	299K	(252K)	(209K)	(77K)	96K	100.8K
Reconciled Depreciation	351K	1.9M	4.2M	5.2M	2.6M	2.4M
Non Operating Income Net Other	(486K)	(1.2M)	1.1M	(538K)	(618.7K)	(649.6K)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for OncoCyte Stock Analysis

When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

OncoCyte Historical Income Statement

About OncoCyte Income Statement Analysis

OncoCyte Corp Income Statement Chart

Other Operating Expenses

Total Operating Expenses

OncoCyte Corp income statement Correlations

OncoCyte Corp Account Relationship Matchups

High Positive Relationship

High Negative Relationship

OncoCyte Corp income statement Accounts

Also Currently Popular

Additional Tools for OncoCyte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Net Income From Continuing Ops	+ 1.0	Income Before Tax
Ebitda	+ 0.99	Operating Income
Income Before Tax	+ 0.98	Ebit

Research Development	- 0.98	Ebit
Research Development	- 0.98	Operating Income
Selling And Marketing Expenses	- 0.97	Net Income From Continuing Ops
Selling And Marketing Expenses	- 0.97	Income Before Tax
Ebitda	- 0.97	Research Development
Ebit	- 0.97	Other Operating Expenses